(VIANEWS) – ESSILORLUXOTTICA (EL.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Medical Instruments & Supplies industry.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| ESSILORLUXOTTICA (EL.PA) | €164.50 | 1.96% | 6.15% |
| SARTORIUS STED BIO (DIM.PA) | €305.10 | 0.47% | 41.43% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ESSILORLUXOTTICA (EL.PA)
1.96% Forward Dividend Yield and 6.15% Return On Equity
EssilorLuxottica Société anonyme engages in design, manufacture, and distribution of ophthalmic lenses, frames, and sunglasses in Europe, Middle East, Africa, Latin America, Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Crizal, Essilor, Eyezen, Stellest, Xperio, Optifog, Satisloh, Barberini, Shamir, Nikon, KODAK Lens, Oakley, OPTIFOG, Ray-Ban, Transitions, Vailux, and Xperio brands. It also provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Alain Mikli, Costa del Mar, Native Eyewear, Luxottica, Sferoflex, Heritage, Sensaya, Miki Ninn, DbyD, Unofficial and Seen, Arnette, Vogue Eyewear, Bolon, Molsion, and Ossé, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of physical stores or its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €0.19.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 865.79. Meaning, the purchaser of the share is investing €865.79 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.15%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on May 22, 2023, the estimated forward annual dividend rate is 3.23 and the estimated forward annual dividend yield is 1.96%.
Moving Average
ESSILORLUXOTTICA’s value is under its 50-day moving average of €172.03 and higher than its 200-day moving average of €159.69.
Volume
Today’s last reported volume for ESSILORLUXOTTICA is 175020 which is 65.42% below its average volume of 506146.
Volatility
ESSILORLUXOTTICA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.40%, a negative 0.14%, and a positive 1.12%.
ESSILORLUXOTTICA’s highest amplitude of average volatility was 1.08% (last week), 0.98% (last month), and 1.12% (last quarter).
More news about ESSILORLUXOTTICA.
2. SARTORIUS STED BIO (DIM.PA)
0.47% Forward Dividend Yield and 41.43% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €4.31.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 70.79. Meaning, the purchaser of the share is investing €70.79 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.43%.
Moving Average
SARTORIUS STED BIO’s worth is under its 50-day moving average of €320.61 and under its 200-day moving average of €331.56.
Revenue Growth
Year-on-year quarterly revenue growth grew by 14.4%, now sitting on 3.49B for the twelve trailing months.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.06%, a negative 0.22%, and a positive 1.60%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 1.34% (last week), 1.21% (last month), and 1.60% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, SARTORIUS STED BIO’s stock is considered to be overbought (>=80).
More news about SARTORIUS STED BIO.
